Olivier Sitbon Selected Research

Pulmonary Arterial Hypertension

1/2022	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
1/2022	COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study.
1/2022	Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation.
1/2022	The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
1/2022	Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension.
1/2022	Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?
1/2022	Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension.
1/2022	Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension.
10/2021	Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
10/2021	Pulmonary hypertension associated with busulfan.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Olivier Sitbon Research Topics

Disease

117	Pulmonary Arterial Hypertension 01/2022 - 03/2002
42	Pulmonary Hypertension 01/2022 - 03/2002
14	Familial Primary Pulmonary Hypertension 01/2020 - 02/2002
10	Connective Tissue Diseases (Connective Tissue Disease) 01/2020 - 07/2006
9	Disease Progression 01/2022 - 06/2004
8	Pulmonary Veno-Occlusive Disease (Veno Occlusive Disease, Pulmonary) 01/2021 - 03/2002
8	Hypertension (High Blood Pressure) 01/2020 - 01/2006
7	Congenital Heart Defects (Congenital Heart Defect) 01/2020 - 06/2005
7	HIV Infections (HIV Infection) 10/2013 - 12/2004
6	Hypoxia (Hypoxemia) 01/2021 - 06/2009
6	Heart Failure 12/2017 - 08/2002
4	Headache (Headaches) 10/2021 - 10/2008
4	Neoplasms (Cancer) 10/2021 - 07/2010
4	Interstitial Lung Diseases (Interstitial Lung Disease) 10/2021 - 08/2011
4	Systemic Scleroderma (Systemic Sclerosis) 08/2016 - 03/2010
4	Infections 04/2016 - 11/2008
3	Nausea 10/2021 - 10/2008
3	Vascular Remodeling 10/2021 - 12/2005
3	Pleural Effusion (Pleural Effusions) 10/2020 - 03/2002
3	Rare Diseases (Rare Disease) 01/2019 - 09/2015
3	Sarcoidosis (Schaumann Disease) 10/2017 - 11/2015
3	Pain (Aches) 12/2015 - 06/2004
3	Portal Hypertension 08/2010 - 11/2008
2	Diarrhea 10/2021 - 12/2015
2	Inflammation (Inflammations) 01/2021 - 10/2013
2	Eisenmenger Complex (Eisenmenger's Syndrome) 05/2017 - 04/2017
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2016 - 05/2012
2	Clinical Deterioration 11/2013 - 08/2002
2	Hereditary Hemorrhagic Telangiectasia 04/2010 - 12/2005
2	Lymphadenopathy 01/2010 - 03/2002
2	Pulmonary Edema 08/2009 - 07/2008
2	Dyspnea (Shortness of Breath) 10/2008 - 08/2002
2	Mixed Connective Tissue Disease (MCTD) 02/2008 - 07/2006
1	Bronchiolitis Obliterans 10/2021
1	Hodgkin Disease (Hodgkin's Disease) 10/2021
1	Ewing Sarcoma (Sarcoma, Ewing) 10/2021
1	B-Cell Lymphoma (Lymphoma, B Cell) 10/2021
1	Respiratory Insufficiency (Respiratory Failure) 10/2021
1	Cystic Fibrosis (Mucoviscidosis) 01/2021
1	Pulmonary Embolism 01/2021

Drug/Important Bio-Agent (IBA)

31	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2021 - 02/2002
17	Endothelin Receptor AntagonistsIBA 01/2020 - 07/2003
13	macitentanIBA 01/2022 - 08/2013
13	selexipagIBA 01/2022 - 12/2015
12	Bosentan (Tracleer)FDA Link 01/2013 - 07/2003
11	Pharmaceutical PreparationsIBA 10/2021 - 06/2004
9	Vasodilator Agents (Vasodilators)IBA 01/2019 - 02/2002
6	ProstaglandinsIBA 01/2022 - 09/2002
6	Endothelins (Endothelin)IBA 12/2012 - 06/2004
5	Epoprostenol ReceptorsIBA 01/2022 - 12/2015
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2012
5	Dasatinib (BMS 354825)FDA Link 10/2020 - 05/2012
5	Phosphodiesterase 5 InhibitorsIBA 01/2020 - 09/2009
5	Sildenafil Citrate (Viagra)FDA Link 01/2014 - 10/2008
5	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2013 - 06/2002
4	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 12/2016 - 06/2008
4	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2013 - 06/2005
3	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 01/2017
3	ProteomeIBA 01/2022 - 01/2017
3	Tadalafil (Cialis)FDA Link 10/2021 - 09/2009
3	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2021 - 10/2014
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2005
3	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2021 - 09/2015
3	treprostinil FDA Link 01/2020 - 01/2007
3	InterferonsIBA 01/2016 - 12/2014
3	Appetite Depressants (Anorectics)IBA 10/2011 - 11/2008
2	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 01/2019
2	Phosphotransferases (Kinase)IBA 10/2021 - 01/2018
2	Carbon MonoxideIBA 01/2021 - 01/2010
2	riociguatIBA 01/2021 - 12/2015
2	MonocrotalineIBA 01/2021 - 11/2010
2	bosutinibIBA 10/2020 - 11/2016
2	Imatinib Mesylate (Gleevec)FDA Link 10/2020 - 01/2016
2	Type II Bone Morphogenetic Protein Receptors (Bone Morphogenetic Protein Receptor Type II)IBA 01/2018 - 02/2016
2	Prostaglandins IIBA 04/2016 - 01/2016
2	DiureticsIBA 07/2013 - 06/2009
2	FenfluramineIBA 11/2012 - 06/2005
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2008 - 07/2006
2	Immunosuppressive Agents (Immunosuppressants)IBA 02/2008 - 07/2006
2	beraprostIBA 06/2004 - 05/2002
1	Busulfan (Busulfex)FDA Link 10/2021
1	Proto-Oncogene Proteins c-kit (Proto-Oncogene Protein c-kit)IBA 10/2021
1	Macrophage Colony-Stimulating FactorIBA 10/2021
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 10/2021
1	Soluble Guanylyl CyclaseIBA 01/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	Growth Factor ReceptorsIBA 01/2021
1	Xanthine OxidaseIBA 01/2021
1	Uric Acid (Urate)IBA 01/2021

Therapy/Procedure

58	Therapeutics 01/2022 - 03/2002
7	Lung Transplantation 01/2022 - 09/2002
6	Liver Transplantation 01/2020 - 09/2014
6	Transplantation 01/2020 - 03/2006
5	Endarterectomy (Thromboendarterectomy) 01/2021 - 04/2007
5	Drug Therapy (Chemotherapy) 01/2019 - 01/2015
4	Contraindications 01/2020 - 01/2006
4	Highly Active Antiretroviral Therapy (HAART) 10/2013 - 09/2008
3	Aftercare (After-Treatment) 10/2021 - 07/2008
2	Heart-Lung Transplantation 08/2017 - 10/2014
2	Intravenous Infusions 04/2016 - 05/2002